Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Human and Mouse VEGFA -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment

Horwitz, Elad, Stein, Ilan, Andreozzi, Mariacarla, Nemeth, Julia, Shoham, Avivit, Pappo, Orit, Schweitzer, Nora, Tornillo, Luigi, Kanarek, Naama, Quagliata, Luca, Zreik, Farid, Porat, Rinnat M., Finkelstein, Rutie, Reuter, Hendrik, Koschny, Ronald, Ganten, Tom, Mogler, Carolin, Shibolet, Oren, Hess, Jochen, Breuhahn, Kai, Grunewald, Myriam, Schirmacher, Peter, Vogel, Arndt, Terracciano, Luigi, Angel, Peter, Ben-Neriah, Yinon, Pikarsky, Eli·2014·Cancer Discovery

Abstract

Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC are limited. We identify a subset of mouse and human HCCs harboring VEGFA genomic amplification, displaying distinct biologic characteristics. Unlike common tumor amplifications, this one seems to work via heterotypic paracrine interactions; stromal VEGF receptors (VEGFR), responding to tumor VEGF-A, produce hepatocyte growth factor (HGF) that reciprocally affects tumor cells. VEGF-A inhibition results in HGF downregulation and reduced proliferation, specifically in amplicon-positive mouse HCCs. Sorafenib—the first-line drug in advanced HCC—targets multiple kinases, including VEGFRs, but has only an overall mild beneficial effect. We found that VEGFA amplification specifies mouse and human HCCs that are distinctly sensitive to sorafenib. FISH analysis of a retrospective patient cohort showed markedly improved survival of sorafenib-treated patients with VEGFA-amplified HCCs, suggesting that VEGFA amplification is a potential biomarker for HCC response to VEGF-A–blocking drugs. Significance: Using a mouse model of inflammation-driven cancer, we identified a subclass of HCC carrying VEGFA amplification, which is particularly sensitive to VEGF-A inhibition. We found that a similar amplification in human HCC identifies patients who favorably responded to sorafenib—the first-line treatment of advanced HCC—which has an overall moderate therapeutic efficacy. Cancer Discov; 4(6); 730–43. ©2014 AACR. See related commentary by Luo and Feng, p. 640 This article is highlighted in the In This Issue feature, p. 621

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0782

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 185

Metadata

Authors
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., Zreik, F., Porat, R. M., Finkelstein, R., Reuter, H., Koschny, R., Ganten, T., Mogler, C., Shibolet, O., Hess, J., Breuhahn, K., Grunewald, M., Schirmacher, P., Vogel, A., Terracciano, L., Angel, P., Ben-Neriah, Y., & Pikarsky, E.
Venue
Cancer Discovery
Published
2014-06-01
Volume
4
Issue
6
Pages
730-743
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2111070218
Cited by
185
References
7
FWCI
9.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human and Mouse VEGFA -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0782
The paper
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., Zreik, F., Porat, R. M., Finkelstein, R., Reuter, H., Koschny, R., Ganten, T., Mogler, C., Shibolet, O., Hess, J., . . . Pikarsky, E. (2014). Human and Mouse VEGFA -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0782

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.